News
Hosted on MSN24d
Viking phase 2b study of NASH candidate hits primary endpoint[Lp(a)], and apolipoprotein C-III (ApoC-III) were observed. Regarding safety, 94% of treatment related adverse events were considered mild or moderate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback